Precision medicine approach to treating neurological disorders
(NASDAQ: PRAX)
(NASDAQ: PRAX)
Investors 3
Mentions in press and media 20
| Date | Title | Description |
| 09.08.2026 | This teen once suffered hundreds of seizures a day. Now he can walk thanks to an experimental drug. | Getting your Trinity Audio player ready... Connor Dalby could not walk for the first 14 years of his life, so his newfound ability to scamper down hallways is miraculous on its own. But the experimental drug that reduced his severe and freq... |
| 29.09.2025 | ReCode Therapeutics Raises Over $29M in Additional Financing | ReCode Therapeutics, a Menlo Park, CA-based clinical-stage genetic medicines company, raised over $29M in additional funding. Backers were undisclosed. It also reported expanded support from the Cystic Fibrosis Foundation (CF Foundation) an... |
| 31.05.2025 | Vima Therapeutics: $60 Million Series A Secured For Advancing Oral Therapy For People With Dystonia And Movement Disorders | Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing led by Atlas Venture, with participation from Access Industries and Canaan. Vima ... |
| 13.01.2025 | Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities | Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide in essential tremor (ET) on track for Q1... |
| 05.04.2024 | Praxis Precision Medicines to Participate in Upcoming April Conferences | BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders... |
| 05.03.2024 | Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results | - |
| 08.01.2024 | Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio | Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion of 45 mg cohort Enrollment for both uli... |
| 15.06.2023 | Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering | - |
| 07.02.2023 | Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results | /EIN News/ -- Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following market close on Thursday, February 9 Topline results expected for each of three ... |
| 06.01.2022 | Esker Therapeutics Announces Name Change to Alumis and Completion of $200 Million Series B Financing to Advance Precision Medicines for Autoimmune Diseases | Alumis, formerly Esker Therapeutics, a precision immunology company backed by Foresite Capital and incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the completi... |
Show more